TOCAGEN INC. WARRANT TO PURCHASE COMMON STOCKTocagen Inc • October 23rd, 2015 • Pharmaceutical preparations • California
THIS CERTIFIES THAT, for value received, Voices Against Brain Cancer (the “Holder”), is entitled to subscribe for and purchase from TOCAGEN INC., a Delaware corporation (the “Company”), 5,000 Exercise Shares at the Exercise Price (each subject to adjustment as provided herein). This Warrant is issued to Holder in connection with that certain Consulting Agreement, dated on even date herewith, by and between Holder and the Company (as the same may be amended from time to time, the “Consulting Agreement”).
LEASELease • October 23rd, 2015 • Tocagen Inc • Pharmaceutical preparations
We establish in favor of Beneficiary our irrevocable and unconditional Letter of Credit numbered is identified above (the “L/C”) for an aggregate amount of $ , expiring at :00 p.m. on or, if such day is not a Banking Day, then the next succeeding Banking Day (such date, as extended from time to time, the “Expiry Date”). “Banking Day” means a weekday except a weekday when commercial banks in are authorized or required to close.
FIRST AMENDMENT TO LABORATORY SERVICES AND LICENSE AGREEMENT (TOCAGEN AND SIEMENS)Laboratory Services and License Agreement • October 23rd, 2015 • Tocagen Inc • Pharmaceutical preparations
This FIRST AMENDMENT TO LABORATORY SERVICES AND LICENSE AGREEMENT (this “Amendment”), effective as of June 19, 2015 (the “Amendment Date”), is made by and between SIEMENS HEALTHCARE DIAGNOSTICS INC., a California corporation having its principal place of business at 511 Benedict Avenue, Tarrytown, NY 10591, USA (“Siemens”), and TOCAGEN INC., a corporation organized under the laws of Delaware and having its principal place of business at 3030 Bunker Hill Street, Suite 230, San Diego, CA 92109, USA (“Tocagen”).
LABORATORY SERVICES AND LICENSE AGREEMENT (TOCAGEN AND SIEMENS)Laboratory Services and License Agreement • October 23rd, 2015 • Tocagen Inc • Pharmaceutical preparations • California
This LABORATORY SERVICES AND LICENSE AGREEMENT (this “Agreement”), effective as of November 17, 2011 (the “Effective Date”), is made by and between Siemens Healthcare Diagnostics Inc., a California corporation having its principal place of business at 511 Benedict Avenue, Tarrytown, NY 10591, United States of America (“Siemens”) and Tocagen Inc., a corporation organized under the laws of Delaware and having its principal place of business at 3030 Bunker Hill Street, Suite 230, San Diego, CA 92109, United States of America (“Tocagen”). Siemens and Tocagen may be individually referred to as a “Party” or collectively as the “Parties” under this Agreement.
LICENSE AGREEMENT GENE DELIVERY SYSTEM AND METHODS OF USE— USC FILE 2862 and HYBRID VECTORS FOR GENE THERAPY—USC FILE 2831Subscription Agreement • October 23rd, 2015 • Tocagen Inc • Pharmaceutical preparations • California
Dr. Kasahara and value the commitment of USC to bring these discoveries to widespread clinical usage for improving the survival of terminally ill cancer patients, including patients with untreatable primary solid tumors as well as those with advanced metastatic disease,” said Harry E. Gruber, MD, Chief Executive Officer of Tocagen.
Voices Against Brain Cancer Research and Development Grant Agreement for Tocagen Inc.Agreement • October 23rd, 2015 • Tocagen Inc • Pharmaceutical preparations • California
This Agreement, dated June 5, 2013, by and between Tocagen Inc. (“Tocagen”), a Delaware corporation with an address at 3030 Bunker Hill Street, Suite 230, San Diego, CA 92109 and Voices Against Brain Cancer (“VABC”) a non-profit corporation with an address at Voices Against Brain Cancer 1375 Broadway, 3rd Floor, New York, NY 10018.
